The incretin approach for diabetes treatment: modulation of islet hormone release by GLP-1 agonism.

Research output: Contribution to journalJournal articleResearchpeer-review

Glucagon-like peptide (GLP)-1 is a gut hormone that stimulates insulin secretion, gene expression, and beta-cell growth. Together with the related hormone glucose-dependent insulinotropic polypeptide (GIP), it is responsible for the incretin effect, the augmentation of insulin secretion after oral as opposed to intravenous administration of glucose. Type 2 diabetic patients typically have little or no incretin-mediated augmentation of insulin secretion. This is due to decreased secretion of GLP-1 and loss of the insulinotropic effects of GIP. GLP-1, however, retains insulinotropic effects, and the hormone effectively improves metabolism in patients with type 2 diabetes. Continuous subcutaneous administration greatly improved glucose profiles and lowered body weight and HbA1c levels. Further, free fatty acid levels were lowered, insulin resistance was improved, and beta-cell performance was greatly improved. The natural peptide is rapidly degraded by the enzyme dipeptidyl peptidase IV (DPP IV), but resistant analogs as well as inhibitors of DPP IV are now under development, and both approaches have shown remarkable efficacy in experimental and clinical studies.
Original languageEnglish
Volume53 Suppl 3
Pages (from-to)S197-204
Publication statusPublished - 2004

Bibliographical note

Keywords: Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Gastrointestinal Hormones; Glucagon; Glucagon-Like Peptide 1; Humans; Islets of Langerhans; Peptide Fragments; Protein Precursors

ID: 8418111